Media about us

• Will Liquid Biopsies Transform Oncology Clinical Trials?

  01 August 2016 Ed Miseta / Clinical Leader

  

  Epic Sciences says it has developed a technology that CEO Murali Prahalad believes will transform oncology trials by identifying and characterizing circulating tumor cells. Those cells have been long recognized as a key part of cancer metastasis. Tumors shed these cells into the circulatory system where they then travel to different parts of the body and, under the right conditions, become the genesis of new tumors.

• Pfizer Partners with NovaMedica to Build Manufacturing Unit in Russia

  20 July 2016 Jerry Boling / Market Digest

  Pfizer Inc. (NYSE: PFE) is currently in the process of developing several manufacturing units in a number of geographical territories all over the world. Just recently, the pharmaceutical giant inked its third major deal in the in the past couple of years. This huge deal involves a partnership with NovaMedica of Russia to establish a manufacturing facility in the country.

• Pfizer agrees to license 30 products to Russian pharma company

  19 July 2016 Life Sciences IP Review

  

  US drugs company Pfizer has entered into a manufacturing and licensing agreement with Russian pharmaceutical company NovaMedica. Pfizer has proposed to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region.

• Pfizer, NovaMedica Announce Strategic Partnership in Russia

  19 July 2016 Drug Discovery & Development

  

  Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region. 

• Pfizer Inc. (PFE) Ready to Reconnoiter Russian Therapeutic Markets

  18 July 2016 Raheel Farooq / Business Finance News

  

  As restrictions in the Western countries rise and growth remains stagnant, Pfizer has taken a wise step to slowly and steadily enter Russia with the establishment of a manufacturing unit. Pfizer Inc. is in the process to develop manufacturing facilities in numerous geographical territories around the globe. Recently, the drug maker signed its third mega deal in the past several years, which is an agreement with Russia’s NovaMedica to build a manufacturing unit.

• Pfizer strikes second deal this year for drug production in Russia

  18 July 2016 Eric Palmer / Fierce Pharma

  

  Pfizer was a little behind some of its peers in establishing local manufacturing in Russia but it's on a roll now, having just announced its third deal in several years. It is hammering out an agreement with Russia’s NovaMedica for a new manufacturing plant. 

• Atlas Genetics mandates UBS for up to USD 30m raise — source

  15 July 2016 Mergermarket

  

  Atlas Genetics (AG), a UK-based, PE-backed point-of-care (POC) diagnostics company, is looking to raise up to USD 30m to fund clinical trials and commercialization, a source familiar with the situation said. The company has developed ultra-rapid, low cost, multiple analyte detection technology for POC use to screen the presence of sexually transmitted infections (STIs) and hospital acquired infections (HAIs).

• Pfizer's Russia Deal Shows Country Still Open To Western Business

  15 July 2016 Kenneth Rapoza / Forbes

  

  U.S. multinational drug maker Pfizer PFE +1.68% is laying down a new foundation in Russia, with a joint venture announced on Wednesday to produce pharmaceuticals domestically.

• Pfizer links with NovaMedica to produce and market drugs in Russia

  15 July 2016 The Pharma Letter

  

  US pharma giant Pfizer (NYSE: PFE) and NovaMedica, a company established by Russian high-technology investment fund Rusnano and American venture health care fund Domain Associates in 2012, have entered into an agreement to cooperate, signalling the development of a new partnership, to bring important medicines to the Russian market.

• Photo: Pfizer and NovaMedica announce a strategic partnership in Russia

  13 July 2016

  

  Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.